Related Experiment Video
Updated: Sep 8, 2025
06:28
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
Published on: June 4, 2020
6.9K
Review article: thromboelastography in liver diseases
Yanglan He1,2, Haijuan Yao1, Walter Ageno3
1Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China.
Alimentary Pharmacology & Therapeutics
|June 14, 2022
Summary
Thromboelastography (TEG) offers a comprehensive assessment of blood clotting in liver disease patients, outperforming conventional tests. TEG can guide transfusions and predict bleeding risks, improving patient outcomes.
Area of Science:
- Hepatology
- Hematology
- Clinical Diagnostics
Background:
- Liver diseases cause complex hemostatic alterations, leading to bleeding and thrombosis.
- Conventional coagulation tests (CCTs) inadequately evaluate these hemostatic changes.
- Thromboelastography (TEG), a whole blood viscoelastic test, globally reflects hemostatic system changes and is increasingly recognized for liver disease evaluation.
Purpose of the Study:
- To review current evidence on TEG's clinical significance in liver diseases.
- To assess TEG's utility in managing hemostatic complications in liver disease patients.
Main Methods:
- Comprehensive literature search on TEG and liver diseases.
- Analysis of studies evaluating TEG's association with disease severity, complications, and transfusion protocols.
Main Results:
- TEG correlates with liver disease severity, infection course, and bleeding/death risk, but not portal venous thrombosis.
- TEG-guided transfusion protocols reduce blood product requirements compared to CCT-guided protocols.
Conclusions:
- TEG provides a more thorough assessment of hemostasis in liver disease than CCTs.
- TEG can potentially assess disease severity, predict bleeding and death risks, and guide blood product transfusion.
- Standardization of TEG for assessing disease severity, clinical events, and guiding transfusions is needed.
